Plasminogen activator inhibitor-1 promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes

SummaryElevated levels of PAI-1 are found in coronary artery disease (CAD) and non-insulin-dependent diabetes (NIDDM). PAI-1 may be involved in the pathogenesis of CAD through suppression of fibrinolysis, alternatively the high levels may result from vascular damage. There is evidence that PAI-1 levels are related to genotype at a PAI-1 promoter polymorphism. Genotype at this 4G/5G polymorphism was determined in 160 NIDDM (90 males and 70 females) patients with (n = 38) or without (n = 122) clinical evidence of CAD. Levels of cholesterol were higher (6.5 vs 5.9 mM, p <0.01) and of PAI-1 tended to be higher (PAI-1 activity 23.0 vs 20.4 U/ml) with CAD. The frequency of the 4G/4G genotype was increased and the 5G/5G genotype decreased, in the group CAD compared to those without (p <0.05). These results suggest that possession of the 4G/4G PAI-1 promoter genotype is a risk factor for the development of CAD in subjects with NIDDM.

Download Full-text

Plasminogen activator inhibitor-1 promoter polymorphism and activity in relation to the extent of coronary artery disease

Blood Coagulation & Fibrinolysis ◽

10.1097/00001721-199509000-00041 ◽

1995 ◽

Vol 6 (6) ◽

pp. 600

Author(s):

N. Ossei-Gerning ◽

M. Stickland ◽

J. I. Wilson ◽

P. J. Grant

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Plasminogen Activator ◽

Plasminogen Activator Inhibitor ◽

Promoter Polymorphism ◽

Plasminogen Activator Inhibitor 1 ◽

Artery Disease ◽

Activator Inhibitor

Download Full-text

Plasminogen Activator Inhibitor-1 Levels in Patients with Chronic Angina Pectoris with or without Angiographic Evidence of Coronary Sclerosis

Thrombosis and Haemostasis ◽

10.1055/s-0038-1645042 ◽

1990 ◽

Vol 63 (03) ◽

pp. 336-339 ◽

Cited By ~ 33

Author(s):

K Huber ◽

I Resch ◽

Th Stefenelli ◽

I Lang ◽

P Probst ◽

...

Keyword(s):

Coronary Artery Disease ◽

Coronary Artery ◽

Angina Pectoris ◽

Plasminogen Activator ◽

Stable Coronary Artery Disease ◽

Plasminogen Activator Inhibitor ◽

Plasminogen Activator Inhibitor 1 ◽

Artery Disease ◽

Activator Inhibitor ◽

Pai 1

SummaryIncreased plasma levels of plasminogen activator inhibitor-1 (PAI-1) have been shown to exist in 40 to 60% of patients with stable coronary artery disease and have been suggested to be responsible for the development of coronary thrombotic complications. However, it is also discussed whether PAI-1 elevation might mainly be due to variables like increased age or to reactive mechanisms caused e.g. by the chest pain itself. To exclude age dependent ui pain related influences, age-matched patients with stable angina pectoris (NHYA II) and angiographically proven coronary artery disease (CAD, n = 16) or without evidence for coronary sclerosis (variant angina, n = 10; angina-like syndrome with normal coronary angiogram, n = 5; non-CAD, n = 15) have been investigated for their plasma PAI-1 activity and t-PA antigen levels. The mean PAI activity in CAD patients (17.5 U/ml) was significantly higher than in non-CAD patients (9.6 U/ml) (p <0.0001). In the CAD patients no significant variation in plasma PAI-1 values could be demonstrated when related to the extent of the disease or to a history of previous myocardial infarction t-PA antigen was also elevated m CAD patients as compared to the non-CAD group (p <0.02). The results suggest therefore a strong correlation between coronary artery disease itself and elevated levels of components of the plasma fibrinolytic system.

Download Full-text